Immunomedics, Inc. was a big mover last session, as the company saw its shares rise nearly 5% on the day. This stock, which remained volatile and traded within the range of $9.48 – $17.16 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen one negative estimate revision in the past two months, while its Zacks Consensus Estimate for the current quarter has also moved lower in the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Immunomedics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Immunomedics, Inc. Price
A better-ranked stock in the Medical – Biomedical and Genetics industry is Acorda Therapeutics, Inc. , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Immunomedics, Inc. was a big mover last session, as the company saw its shares rise nearly 5% on the day. This stock, which remained volatile and traded within the range of $9.48 – $17.16 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen one negative estimate revision in the past two months, while its Zacks Consensus Estimate for the current quarter has also moved lower in the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Immunomedics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Immunomedics, Inc. Price
A better-ranked stock in the Medical – Biomedical and Genetics industry is Acorda Therapeutics, Inc. , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>